Antibody-drug Conjugate Information
General Information of This Antibody-drug Conjugate (ADC)
| ADC ID |
DRG0BRCRW
|
|||||
|---|---|---|---|---|---|---|
| ADC Name |
CCR4-IL2 IT
|
|||||
| Synonyms |
CCR4-IL2-IT; CCR4-IL2IT
Click to Show/Hide
|
|||||
| Drug Status |
Investigative
|
|||||
| Antibody Name |
CCR4IL2
|
Antibody Info | ||||
| Antigen Name |
C-C chemokine receptor type 4 (CCR4)
|
Antigen Info | ||||
| Payload Name |
Undisclosed
|
|||||
| Therapeutic Target |
Stimulator of interferon genes protein (STING1)
|
Target Info | ||||
| Linker Name |
Undisclosed
|
|||||
General Information of The Activity Data Related to This ADC
Full List of Activity Data of This Antibody-drug Conjugate
Revealed Based on the Cell Line Data
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal Inhibitory Concentration (IC50) | 0.45 pM | Positive CCR4 expression (CCR4 +++/++) | ||
| Method Description |
A comparison of the in vitro efficacy of CCR4-IL2 IT versus brentuximab to human CD25+CCR4+CD30+ Hut102/6TG cells was performed using a luminescent-based cell viability assay.
|
||||
| In Vitro Model | Cutaneous T cell lymphoma | HUT102/6TG cells | Homo sapiens | ||
References